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Purpose: The prognosis of breast cancer has been consistently improving. We an-
alyzed our cohort of breast cancer patients with a long-term follow up at a single 
center over time. Materials and Methods: A total of 1889 patients with known 
cancer stages were recruited and analyzed between January 1991 and December 
2005. Patients were classified according to the time periods (1991--1995; 1996--
2000; 2001--2005). To determine intrinsic subtypes, 858 patients whose human 
epidermal growth receptor-2 status and Ki67 were reported between April 2004 
and December 2008 were also analyzed. Results: At a median follow up of 9.1 
years, the 10-year overall survival (OS) rate was 80.5% for the entire cohort. On 
multivariate analysis for OS and recurrence-free survival (RFS), the time period 
was demonstrated to be a significant factor independent of conventional prognos-
tic markers. In the survival analysis performed for each stage (I to III), OS and 
RFS significantly improved according to the time periods. Adoption of new agents 
in adjuvant chemotherapy and endocrine therapy was increased according to the 
elapsed time. In the patients with known subtypes, OS and RFS significantly dif-
fered among the subtypes, and the triple-negative subtype showed the worst out-
come in stages II and III. Conclusion: In the Korean breast cancer cohort with a 
long-term follow up, our data show an improved prognosis over the past decades, 
and harbor the contribution of advances in adjuvant treatment. Moreover, we pro-
vided new insight regarding comparison of the prognostic impact between the tu-
mor burden and subtypes.
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INTRODUCTION
Breast cancer is the most common cancer in women, with about 1.5 million new 
cases being diagnosed annually worldwide, a lifetime risk of up to 12%, and a risk 
of death of up to 5% in Western countries.1 The incidence of breast cancer in Ko-
rea has been increasing constantly, although it remains low compared with its inci-
dence in Western countries.2-5 According to the hospital-based cancer registry 
Original Article http://dx.doi.org/10.3349/ymj.2014.55.5.1187pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 55(5):1187-1195, 2014
Sung Gwe Ahn, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 5   September 20141188
MATERIALS AND METHODS
　　　
Patient population
A prospectively maintained database of breast cancer pa-
tients treated at Gangnam Severance Hospital, Seoul, Re-
public of Korea, was used to identify patients who under-
went operation with a diagnosis of breast cancer between 
January 1991 and December 2005. The period was divided 
into three corresponding periods: 1991--1995, 1996--2000, 
and 2001--2005. The follow-up protocol included planned 
regular visits every 6 months and requests for missed ap-
pointments with a telephone call were made to minimize 
patient loss and raise the accuracy of survival data. The last 
update of the clinical database was in September 2012. 
Among the patients receiving an operation, six male pa-
tients with breast cancer, one patient with occult cancer, and 
18 patients with breast cancer of non-epithelial origin (such 
as a phyllodes tumor, sarcoma, or lymphoma) were exclud-
ed. For survival analysis based on stages, patients with an 
unknown tumor size and nodal status were also excluded. 
Bilateral breast cancer was counted as a single patient. Fi-
nally, 1889 patients were included in the primary analysis. 
The institutional review board of Gangnam Severance Hos-
pital, Yonsei University, Seoul, Korea, approved the study 
to be in accordance with good clinical practice guidelines 
and the Declaration of Helsinki (Local IRB number: #3-
2013-0152). The need for informed consent was waived 
due to the retrospective design.
For analysis using intrinsic subtypes, we required infor-
mation regarding HER-2 status. However, we reported reli-
able HER-2 data from the institute for April 2002. There-
fore, to overcome a small sample size of analysis based on 
subtypes, with a restriction to this analysis, we extended the 
study period to December 2008. As a result, 858 patients 
treated between April 2004 and December 2008 were in-
cluded in the present analysis. 
The staging system was based on the American Joint 
Committee on Cancer (AJCC), 6th edition.14 We revised the 
final stage according to the criteria. In synchronous bilateral 
breast cancer, the higher stage between two tumors was se-
lected. In metachronous bilateral breast cancer, the stage of 
the first cancer was chosen. In patients receiving neoadju-
vant chemotherapy, the clinical stage before neoadjuvant 
chemotherapy was applied. 
During the process of collecting information on adjuvant 
treatment, we investigated the change in drug regimen ac-
called the Korea Central Cancer Registry, the age-standard-
ized breast cancer incidence rate per 100000 was 20.9 in 
1999, and it was exponentially elevated to 39.8 in 2010, 
providing an annual percent change of 6.3%.6 Based on this 
national-wide database, the breast was the second most 
common cancer site following the thyroid in year 2010 and 
comprised 14.3% of all female cancers.6 
Although there is an increasing incidence of breast can-
cer in Korea, the survival outcome of breast cancer patients 
has also markedly improved. The 5-year survival rate be-
tween 1993 and 1995 was 78.0%, and that rate jumped up 
to 89.5% between 2003 and 2007.2 Many reports have pro-
vided relevant explanations for the recent survival improve-
ment in breast cancer patients. In part, the incline in surviv-
al rate can be attributed to nationwide screening programs, 
with expansion of a proportion of patients with ductal carci-
noma in situ and early breast cancer.7 Other reasons for these 
improvements are the advances in adjuvant treatment, which 
includes the increasing use of adjuvant anthracycline-based 
regimens or taxane-based regimens8,9 and clinical adoption 
of new agents: for instance, aromatase inhibitors for hor-
mone receptor-positive tumors and the monoclonal anti-
body trastuzumab for human epidermal growth factor re-
ceptor-2 (HER-2)-positive tumors.10,11 However, almost all 
these studies have been reported in Western countries, in 
which Asian races had seldom participated. In contrast to 
these countries, very few investigations have been reported 
to explain the underlying cause of the survival improve-
ment of Korean breast cancer patients over time. Thus, it 
would be clinically relevant to discriminate the influences 
between the incremental changes in early-stage cancer and 
time periods that suggest the advancement in cancer man-
agement.
Recently, molecular subtyping of breast cancer was logi-
cally accepted in clinical practice12,13 hence, the prognostic 
influence of the subtypes has become increasingly impor-
tant. Therefore, we explored survival analysis according to 
subtype in the present investigation.
To discriminate the impact on survival between tumor 
stage and time periods, we analyzed survival outcome ac-
cording to the time trend at a single institution. We sought to 
delineate the improving trend of survival outcome according 
to time periods at each stage and uncover factors of survival 
prolongation using our database of well over 1000 patients. 
To evaluate a prognostic influence of the intrinsic subtypes, 
we compared survival among subtypes defined by immu-
nohistochemistry (IHC) markers.
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Kaplan-Meier method were compared using the log-rank 
test. Factors, which were significantly demonstrated in the 
univariate analyses, were used in the multivariate analyses. 
A Cox proportional hazards regression model was used to 
assess the effect of each potential prognostic variable on 
survival. A p value <0.05 was considered significant. The 
software used to perform these analyses was the SPSS ver-
sion 18 (SPSS Inc., Chicago, IL, USA).  
RESULTS
 
Demographic characteristics
In 1889 patients, we compared baseline characteristics ac-
cording to the corresponding time period (Table 1). Accord-
ing to the elapsed time, patients aged 40--49 years and 50--59 
years showed a peak breast cancer incidence (41.0% and 
23.1%, respectively), followed by patients aged 30--39 years 
(20.2%). These peak ages are concordant with breast cancer 
in Korea and are different from those observed in Western 
countries. In our cohort, pure in situ carcinoma was diag-
nosed in 9.3% of the patients, and invasive carcinoma oc-
curred in 91.7% of the patients. The composition of T stage 
was not significantly changed, but the proportion of N stage 
showed a significant change according to the time period. As 
a result, the proportion of stage 0 and I increased from 37.3% 
from 1991 to 1995 to 42.7% during 15 years. The composi-
tion of high histologic grade was not associated with elapsed 
time (Table 1). The rate of positive ER among the patients 
with known ER status was not significantly different (58.9% 
in 1991--1995, 59.3% in 1996--2000, and 61.7% in 2001--
2005; p=0.528). The results were similar for PR. 
Survival outcomes
During the follow-up periods, 303 breast cancer-specific 
mortalities and 49 non-cancer related deaths occurred. At a 
median follow up of 9.1 years, the 10-year OS rate was 
80.5% [95% confidence interval (CI), 79.5--81.5%] for the 
entire cohort. Tumor stages according to AJCC classification 
of the 1889 patients were as follows: stage 0 in 176 (9.3%), 
stage I in 540 (28.6%), stage II in 804 (42.6%), stage III in 
871 (17.4%), and stage IV in 40 (2.1%) patients. The 10-year 
OS rates by each stage were 97.3% (95% CI, 96.0--98.6%) 
for stage 0, 91.4% (95% CI, 90.0--92.8%) for stage I, 83.5% 
(95% CI, 82.0--84.0%) for stage II, 53.1% (95% CI, 50.0--
56.2%) for stage III, and 12.0% (95% CI, 6.7--17.3%) for 
stage IV.   
cording to the time period. We obtained information regard-
ing changing regimens with endocrine therapy. Radiothera-
py data were not included.
Subtyping
With regard to biomarker assays, before February 1999, es-
trogen receptor (ER) status was determined using the li-
gand binding assay, and tumors were considered ER posi-
tive with a score greater than 10 fmol/mg.15 After February 
1999, the IHC method for ER staining was introduced and 
replaced the biochemical method. Likely, progesterone re-
ceptor (PR) expression was measured based on the ligand 
binding assay before 1999 and the IHC method after that 
time. As mentioned earlier, refined IHC evaluation for HER-
2 was established from April 2002 at our institute. HER-2 
positivity was assessed by three positive results on IHC ex-
amination or fluorescence in situ hybridization amplifica-
tion. Since March 2002, Ki67 labelling index using MIB-1 
monoclonal antibodies was clinically applied in our patho-
logic laboratory. Ki67 expression was measured by an ex-
perienced pathologist and was presented as a percentage 
score (from 0 to 100). Ki67 staining was stratified as a high 
or low score with a cut-off value of 14%.         
For the intrinsic sub-classification, we analyzed the 858 
patients with information regarding ER, PR, HER-2, and 
Ki67 status. According to the criteria suggested by the St. 
Gallen panelists,16 we classified four subtypes as follows: 
luminal A (ER-positive and/or PR-positive, HER-2-nega-
tive and Ki-67 <14%); luminal B (ER-positive and/or PR-
positive, HER-2-negative, and Ki67 ≥14% or ER-positive 
and/or PR-positive and HER-2-positive, and any Ki67); 
HER-2 (ER-negative, PR-negative, and HER-2-positive); 
and triple-negative breast cancer (ER-negative, PR-nega-
tive, and HER-2-negative). 
We reviewed the medical records for any discrepancies 
in the information and pathologic data of the patients and 
summarized the clinicopathologic characteristics of the pa-
tients and details of adjuvant treatment.
Statistical analysis
Discrete variables were compared by χ2 test. Overall sur-
vival (OS) was measured from the date of the first curative 
surgery to the date of the last follow up or death from any 
cause during follow up. Recurrence-free survival (RFS) was 
measured from the date of the first curative surgery to the 
date of the first locoregional or distant metastasis, or death 
without any type of relapse. Survival curves based on the 
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surgery were not completely registered in the database; 
thus, our data could not represent survival of stage IV dis-
ease. Therefore, to evaluate the effect of the time periods, 
we performed survival analysis in patients with stage I to 
Survival improvement according to the time period for 
patients with stage I--III disease
We noted the increased rate of early breast cancer over 
time. Additionally, the patients in stage IV without breast 
Table 1. Baseline Characteristics Based on the Time Periods
Time cohort All patients 1991--1995 1996--2000 2001--2005 p value
n 1889 391 726 772
Age in yrs 0.552
    <30     52   12   23   17
    30--39   383   81 168 185
    40--49   775 162 297 316
    50--59   437   84 168 185
    60--69   184   40   63   81
    70--79     51   10   17   24
    ≥80       7     2     0     5
Histologic type <0.001
    In situ, carcinoma   176   41   57   78
    IDC 1528 327 604 607
    ILC     41     3   18   20
    Medullary     50   11   23   16
    Mucinous     40     6   13   21
    Tubular     14     2     7     5
    Others     26     0     3   23
T stage 0.259
    Tis   174   43   54   77
    T1   746 152 278 316
    T2   823 163 337 323
    T3   146   33   57   56
N stage <0.001
    N0 1129 233 406 490
    N1   439   71 204 164
    N2   162   40   52   70
    N3   159   47   64   48
Stage <0.001
    In situ   176   43   56   77
    I   540 103 184 253
    II   804 150 350 304
    III   329   87 120 122
    IV     40     8   16   16
Histologic grade 0.150
    I, II 1052 222 400 430
    III   347   76 147 124
    Unknown   490   93 179 218
Estrogen receptor 0.528
    Positive   993 175 366 452
    Negative   651 122 251 278
    Unknown   245   94 109   42
Progesterone receptor 0.623
    Positive 1014 180 389 445
    Negative   628 117 226 285
    Unknown   247   94 111   42
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
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2005, whereas it was 33.0% during 1991--1995. At our in-
stitute, taxane-related regimens were first prescribed during 
1996--2000. Since then, they have become widely used in 
clinical practice, with 37.1% of patients receiving adjuvant 
chemotherapy during 2001--2005.
Survival based on molecular subtype
To evaluate the prognostic value of breast cancer subtypes, 
we performed survival analysis with subtypes defined by 
IHC markers. Stages of all patients were also I--III. Among 
the 858 patients with known molecular subtypes, luminal 
A, luminal B, HER-2, and triple-negative subtypes were 
375 (43.8%), 190 (22.1%), 134 (15.6%), and 159 (18.5%), 
respectively. At a median follow up of 5.5 years, OS and 
RFS significantly differed among the groups classified by 
subtypes on the log-rank test (Fig. 3A and B). In univariate 
analysis for OS, luminal A showed the best survival, where-
as the triple-negative type showed the worst outcome (Fig. 
3A). The 5-year RFS rate was 94.2% in luminal A, 87.5% 
in luminal B, 85.4% in HER-2, and 85.9% in triple-nega-
tive subtypes (Fig. 3B).  
To compare the influence on survival of the subtypes 
with tumor burden, we conducted survival analysis using 
the subtypes according to each stage. Among 326 patients 
with stage I disease, a significant difference in RFS and OS 
was not found among the subtypes (p=0.517 and p=0.747, 
respectively) (Fig. 3C and D). Of the 532 patients with 
stage II and III disease, RFS and OS were significantly dif-
ferent according to subtype (p<0.001 and p=0.003, respec-
tively) (Fig. 3E and F). For these patients in stage II and III, 
the triple-negative subtype showed a worse OS than the 
best results observed in the luminal A subtype (Fig. 3E). 
These findings suggest that the influence of subtype has 
III disease according to the time period. In 1673 patients 
with stage I--III disease, the 7-year OS rates were 76.2% for 
1991--1995, 82.1% for 1996--2000, and 93.7% for 2001--
2005 (p<0.001) (Fig. 1A). The 7-year RFS rates were 65.6% 
for 1991--1995, 75.4% for 1996--2000, and 88.2% for 2001--
2005 (p<0.001) (Fig. 1B).   
To discriminate between the impact of tumor stage and 
the time periods on survival, we performed survival analy-
sis by each stage (Fig. 2). In patients with stage I disease, 
survival significantly differed according to the time period. 
For these patients, however, OS and RFS did not seem to 
be much different between the 1991--1995 and 1996--2000 
time periods (Fig. 1). In contrast to stage I, the difference 
between OS and RFS became larger in stage II or III by ev-
ery time period (Fig. 2C-F). We found that mortality reduc-
tion and recurrence reduction according to the time period 
were mainly achieved in stages II--III. 
In the final step, we performed multivariate survival anal-
ysis (Table 2). In this analysis, the time factor was demon-
strated to be a significant prognostic factor for OS and RFS 
independent of age, tumor size, nodal status, and ER status.
Change in adjuvant chemotherapy and endocrine 
therapy
We investigated the regimens of chemotherapy and endo-
crine therapy, which reflected the advancement of cancer 
management (Table 3). For endocrine therapy, selective ER 
modulators were the only option during 1991--1995. How-
ever, aromatase inhibitors were introduced clinically during 
1996--2000, and their use was expanded during 2001--2005. 
For chemotherapy, the use of an anthracycline-based regi-
men was constantly expanded during 15 years. The rate of 
anthracycline-based regimen use was 57.6% during 2001--
Fig. 1. Kaplan-Meier plots for overall survival (OS) and recurrence-free survival (RFS) according to the time period among patients with 
stage I--III disease. All p values are measured by the log-rank test. (A) OS (p<0.001). (B) RFS (p<0.001).
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role in the survival improvement of Korean breast cancer 
patients. Until now, this advance in survival outcome by 
time trend has been mainly explained by the increasing pro-
portions of early-stage cancer. It has been suggested that the 
wide application of newly developed agents in chemothera-
py or endocrine therapy may be an underlying cause. In our 
results, an incremental trend in the proportion of stage 0 
and I disease was similarly noted (37.3% during 1991--
1995 to 42.7% during 2001--2005). 
To discriminate the influences on survival improvement 
been attenuated in survival of early breast cancer.
DISCUSSION
In the first part of the present study, we evaluated the fac-
tors associated with survival improvement in breast cancer 
using the database of a single institution, which is prospec-
tively maintained and less affected by an interdisciplinary 
variability. We found that the time period played a major 
Fig. 2. Kaplan-Meier plots for overall survival (OS) and recurrence-free survival (RFS) according to the time period in each stage (I--III). All 
p values are measured by the log-rank test. (A) OS in stage I (p=0.002). (B) RFS in stage I (p=0.039). (C) OS in stage II (p<0.001). (D) RFS in 
stage II (p<0.001). (E) OS in stage III (p<0.001). (F) RFS in stage III (p<0.001).
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pansion of early-stage breast cancer to an important reason, 
and comparisons of survival in the same stage were not per-
formed. Our results highlighted that survival improvement 
by time trend was accomplished in each stage (stage I--III), 
as well as in the overall population. 
In the second part of our study analyzing survival out-
come with breast cancer intrinsic subtypes, our data from a 
cohort with known intrinsic subtypes provided results simi-
lar to those of previous studies in which the triple-negative 
subtype showed the worst outcome.17-19 Furthermore, to 
isolate the prognostic influence of the subtype from the ef-
fect of tumor burden, we conducted survival analysis using 
the subtypes in stage I or stages II and III. In stages II and 
III, survival outcome significantly varied according to sub-
type. By contrast, in stage I, a significant difference was not 
observed in survival outcome among the subtypes, imply-
ing that the intrinsic subtypes less affect prognosis in early 
breast cancer. However, conflicting data have been reported 
that the subtypes play an important role in prognosis in ear-
ly breast cancer,20,21 even in node-negative T1ab breast can-
cer.22 This discrepancy might be explained by the expanded 
use of chemotherapy in ER-negative patients because we 
between increases in early breast cancer and advances of 
adjuvant therapy, we performed multivariate survival anal-
ysis, including the time factor and survival analysis in each 
stage among the patients with AJCC stages I--III. The con-
tributions of the time factor to survival improvement were 
observed independent of other important factors such as 
age, tumor size, nodal status, and ER status (Table 2). 
Moreover, survival gains brought by elapsed time have 
been achieved in each stage (Fig. 2). Obviously, this phe-
nomenon was remarkable in stages II and III. To indirectly 
evaluate the influence of changing regimens in adjuvant 
therapy, we compared the types of regimens used in endo-
crine therapy and chemotherapy among the time periods, and 
our analysis showed that the proportion of new agents of 
chemotherapy and endocrine therapy incrementally changed 
over time. Advancement in adjuvant therapy may be asso-
ciated with survival improvement of breast cancer patients 
during the investigated period, particularly in the patients 
with locally advanced breast cancer. 
In the previous study based on a large cohort of Korean 
breast cancer patients,5 an enhanced survival outcome by 
time trend was reported. However, they suggested the ex-
Table 3. Change in Adjuvant Therapy Regimen for Patients with Stage I--III Disease Based on the Time Period
Time cohort All patients 1991--1995 1996--2000 2001--2005 p value
Endocrine therapy <0.001
    SERM 758 135 283 340
    AI 101     0   39   62
Chemotherapy <0.001
    CMF 545 128 387   30
    Anthracycline-based regimen 538   63 148 327
    Taxane-based regimena* 248     0   37 211
SERM, selective estrogen receptor modulator; AI, aromatase inhibitor; CMF, cyclophosphamide-methotrexate-5-fluorouracil. 
*Taxane-based regimen included the sequential regimen such as anthracycline followed by taxane.
Table 2. Multivariate Models for Survival Outcomes during 15 Years
Characteristics         
Overall Recurrence-free
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Age in yrs
    ≤35 vs. >35 0.60 0.44--0.81 0.001 0.49 0.38--0.64 <0.001
Tumor size
    ≤2 cm vs. >2 cm 1.64 1.26--2.14 <0.001 1.55 1.24--1.95 <0.001
Nodal status
    Positive vs. Negative 2.98 2.30--0.86 <0.001 2.83 2.27--3.54 <0.001
Estrogen receptor status
    Positive vs. Negative 0.68 0.54--0.86 0.001 0.80 0.65--0.99   0.039
Time period
    1991--1995 vs. 1996--2000 0.58 0.45--0.76 <0.001 0.61 0.48--0.77 <0.001
    1991--1995 vs. 2001--2005 0.23 0.17--0.33 <0.001 0.29 0.22--0.39 <0.001
CI, confidence interval.
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clinical trials, showed heterogeneity in adjuvant therapy. 
The reasons contributing to survival improvement in each 
stage are not fully elucidated and the influence of advance-
ment in adjuvant therapy could not be directly evaluated.
However, our findings have advantages over these limita-
tions regarding the well-outlined survival improvement by 
time trend, and the unique analysis with the intrinsic sub-
types based on a single-center database interfered less with 
heterogeneous treatment policies. The strengths of the study 
actively used chemotherapy for ER-negative tumors, even 
for small tumors (data not shown). To solve contradictory 
results between our data and other studies, longer follow-up 
duration is required to delineate a survival pattern according 
to subtype because survival outcome in stage I is very favor-
able (the estimated 10-year OS rate is 90.9% in stage I).
The present retrospective study possesses several limita-
tions. The retrospective design is associated with inherent 
limitations. The patients in our study, which is not based on 
Fig. 3. Kaplan-Meier plots for overall survival (OS) and recurrence-free survival (RFS) according to subtype. All p values are measured by 
the log-rank test. (A) OS by subtype in stages I--III (p=0.002). (B) RFS by subtype in stages I--III (p=0.039). (C) OS by subtype in stage I 
(p=0.517). (D) RFS in stage I (p=0.747). (E) OS by subtype in stages II--III (p=0.003). (F) RFS by subtype in stages II--III (p<0.001). HER-2, hu-
man epidermal growth factor receptor-2.
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84.
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13. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees 
CA, et al. Molecular portraits of human breast tumours. Nature 
2000;406:747-52.
14. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, 
et al. Staging system for breast cancer: revisions for the 6th edition 
of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 
83:803-19.
15. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, 
Badve S, et al. American Society of Clinical Oncology/College of 
American Pathologists guideline recommendations for immuno-
histochemical testing of estrogen and progesterone receptors in 
breast cancer (unabridged version). Arch Pathol Lab Med 2010; 
134:e48-72. 
16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, 
Senn HJ, et al. Strategies for subtypes--dealing with the diversity 
of breast cancer: highlights of the St. Gallen International Expert 
Consensus on the Primary Therapy of Early Breast Cancer 2011. 
Ann Oncol 2011;22:1736-47.
17. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Con-
way K, et al. Race, breast cancer subtypes, and survival in the 
Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
18. Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, et al. Triple 
negative breast cancer in Korea-distinct biology with different im-
pact of prognostic factors on survival. Breast Cancer Res Treat 
2010;123:177-87. 
19. O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes 
WD, et al. Intrinsic breast tumor subtypes, race, and long-term 
survival in the Carolina Breast Cancer Study. Clin Cancer Res 
2010;16:6100-10.
20. Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, et al. Clini-
cal relevance of TNM staging system according to breast cancer 
subtypes. Ann Oncol 2011;22:1554-60. 
21. Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast 
cancer subtypes on breast cancer specific survival, distant metasta-
ses and local relapse rates in conservatively managed early stage 
breast cancer: a retrospective clinical study. Eur J Surg Oncol 
2011;37:876-82. 
22. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam 
F, Chavez-Macgregor M, et al. Age and survival estimates in pa-
tients who have node-negative T1ab breast cancer by breast can-
cer subtype. Clin Breast Cancer 2011;11:325-31. 
include a large patient population, the long-term follow up 
duration, and the uniform initial staging and follow-up sur-
veillance protocol. Our attempt to ameliorate survival in Ko-
rean breast cancer patients will be facilitated by the findings 
that we were successful in improving outcome over time.
In conclusion, the present study provides significant evi-
dence of improvement in the prognosis of Korean breast 
cancer patients with AJCC stage I--III during the recent 15 
years, while considering the beneficial effect of significant 
prognostic factors. Our data imply that advancement of ad-
juvant treatment plays an integral part in producing a sur-
vival benefit and in expanding the therapeutic options for 
breast cancer patients. Moreover, we concordantly showed 
a clinical significance of the intrinsic subtypes and provided 
a novel insight regarding comparison of the prognostic im-
pact between tumor burden and subtypes.
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